131 results
Page 3 of 7
8-K
EX-99.1
ju0c4zm
15 May 23
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
S-4
EX-2.2
m5j8pb
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-2.3
2oeuto7hd e3asdbd
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
bx7r y4nhnzu
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.14
hpbxmnyy0c
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.9
exnwafl0q1
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.15
o1u8qh
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.19
3osuwv1v4bdy83nx02zb
11 May 23
Registration of securities issued in business combination transactions
9:09am
425
zck2197j87v1sob
18 Apr 23
Business combination disclosure
5:12pm
6-K
EX-99.1
bmllcrbiwlqcjwr0zrxu
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.2
oqeslpqt b2ghfb3oy
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.3
pim5nf
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.1
7k89a77r mz6e
1 Sep 22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
5:16pm
6-K
yl9hyqa6pk3ygdk ggy1
1 Sep 22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
5:16pm
6-K
EX-99.3
mzens46ijsc5dh8tnd4
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.1
0d9ri4h24j
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
k4xzkjw5yo6n3
2 Aug 22
VBL Therapeutics Announces Workforce Reduction
8:32am
6-K
EX-99.1
we5ij81c
2 Aug 22
VBL Therapeutics Announces Workforce Reduction
8:32am
6-K
EX-99.1
ozr urfmrx3cpfj4
19 Jul 22
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
4:09pm
6-K
EX-99.2
lkmifwu39h1c
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm